Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is comparing the efficacy of tacrolimus and mycophenolate mofetil for the initial therapy of active lupus glomerulonephritis.
Condition or disease
Drug: tacrolimusDrug: mycophenolate mofetil
Patients with biopsy proven active lupus nephritis will be randomized to receive tacrolimus or mycophenolate mofetil, on top of corticosteroids, for initial treatment. Efficacy and adverse effects will be compared.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who fulfill at least 4 of the ACR criteria for SLE
Age >= 18 years
Biopsy proven active lupus glomerulonephritis (ISN/RPS class III/IV/V)
Serum creatinine < 200 umol/L at the time of randomization
Patients who refuse to be randomized for treatment
Patients who prefer treatment with conventional agents such as oral or intravenous CYC for various reasons
Serum creatinine >= 200 umol/L at the time of randomization
Patients without renal biopsy or those who have lupus nephritis ISN/RPS class I,II,VI
Patients who are pregnant or plan for pregnancy within 12 months after randomization